尿肝型脂肪酸结合蛋白是1型糖尿病患者卒中和死亡的独立预测因子
在2329例芬兰1型糖尿病患者队列中(中位随访14.1年),基线尿肝型脂肪酸结合蛋白与肌酐比值可独立于传统危险因素预测卒中和死亡,进一步校正eGFR或AER后仍显著;但校正AER后不能预测其他心血管终点。
要点
- 尿L-FABP可独立于传统危险因素预测1型糖尿病患者卒中(HR 1.33)。
- 尿L-FABP可独立于传统危险因素预测1型糖尿病患者死亡(HR 1.34)。
- 校正AER后,尿L-FABP不能预测冠心病、外周血管病及总体CVD事件。
核心结论
- 尿肝型脂肪酸结合蛋白是1型糖尿病患者卒中和死亡的独立预测因子。
- 尿L-FABP在传统危险因素基础上改善了卒中和死亡的AUC,但加入AER或eGFR后未显示重分类获益。
研究设计与样本
- 芬兰1型糖尿病队列研究,纳入2329例1型糖尿病患者。
- 中位随访14.1年,基线尿样测定L-FABP与肌酐比值。
- 采用Cox回归模型评估尿L-FABP的预测价值,并用一组统计指标评估其对心血管结局和死亡的附加预测获益。
主要发现
- 尿L-FABP独立于传统危险因素预测卒中(HR 1.33 [95% CI 1.20, 1.49]),进一步校正eGFR后HR 1.28 [95% CI 1.14, 1.44],校正AER后HR 1.24 [95% CI 1.06, 1.44]。
- 尿L-FABP独立于传统危险因素预测死亡(HR 1.34 [95% CI 1.24, 1.45]),进一步校正eGFR后HR 1.29 [95% CI 1.18, 1.39],校正AER后HR 1.22 [95% CI 1.09, 1.36]。
- 尿L-FABP预测能力与eGFR或AER相当,并在传统危险因素基础上改善卒中和死亡的AUC;但在传统危险因素基础上加入AER或eGFR后,对卒中或死亡无重分类获益(IDI/NRI)。
- 校正AER后,尿L-FABP不是其他心血管终点(冠心病、外周血管病和总体CVD事件)的预测因子。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: In type 1 diabetes, cardiovascular disease (CVD) and diabetic nephropathy progress in parallel, thereby potentiating the risk of premature death during their development. Since urinary liver-type fatty acid binding protein (L-FABP) predicts the progression of diabetic nephropathy, the aim of this study was to investigate whether urinary L-FABP also predicts cardiovascular outcomes and mortality. METHODS: We tested our hypothesis in a Finnish cohort of 2329 individuals with type 1 diabetes and a median follow-up of 14.1 years. The L-FABP to creatinine ratio was determined from baseline urine samples. The predictive value of urinary L-FABP was evaluated using Cox regression models, while its added predictive benefit for cardiovascular outcomes and mortality was evaluated using a panel of statistical indexes. RESULTS: Urinary L-FABP predicted incident stroke independently of traditional risk factors (HR 1.33 [95% CI 1.20, 1.49]) and after further adjustment for eGFR (HR 1.28 [95% CI 1.14, 1.44]) or AER (HR 1.24 [95% CI 1.06, 1.44]). In addition, it predicted mortality independently of traditional risk factors (HR 1.34 [95% CI 1.24, 1.45]), and after adjustment for eGFR (HR 1.29 [95% CI 1.18, 1.39]) or AER (HR 1.22 [95% CI 1.09, 1.36]). Urinary L-FABP was as good a predictor as eGFR or AER, and improved the AUC for both outcomes on top of traditional risk factors, with no reclassification benefit (integrated discrimination improvement/net reclassification improvement) for stroke or mortality when AER or eGFR were added to traditional risk factors. However, urinary L-FABP was not a predictor of other cardiovascular endpoints (coronary artery disease, peripheral vascular disease and overall CVD events) when adjusted for the AER. CONCLUSIONS/INTERPRETATION: Urinary L-FABP is an independent predictor of stroke and mortality in individuals with type 1 diabetes.
引用
- Panduru NM, Forsblom C, Saraheimo M, et al. Urinary liver-type fatty acid binding protein is an independent predictor of stroke and mortality in individuals with type 1 diabetes. Diabetologia. 2017. PMID: 28601908. doi:10.1007/s00125-017-4328-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。